All In Biotech

Drug Trial Radar · NCT02013115

Curosurf/Budesonide for Infants With Respiratory Distress Syndrome

Last checked: Nov 20, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jan 1, 2015

Primary completion

Oct 30, 2017

Study completion Oct 30, 2017

Sponsor

Sponsor type
Academic, hospital or other
First posted
Dec 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 12 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Infants showing high local pulmonary inflammation diagnosted by respiratory distress syndrome usually need the second or more pulmonary surfactant and is easier to developing to Brochopulmonary. Cursurf is used worldwide in infants with respiratory distress syndrome, Budesonide is a glucocorticoid with a high local anti-inflammatory effect.Our hypothesis is Cursurf combined with Budesonide could reduced the need of Cursurf and incidence of Brochopulmonary dysplasia.

Conditions

  • Respiratory Distress Syndrome

Interventions

  • BudesonideDrug

    Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. need of pulmonary surfactantTime frame: one month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.